Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2024-04-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于向控股股东借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction where the company plans to borrow funds from its controlling shareholders. It details the terms of the loan, the parties involved, the approval process by the board and independent directors, and the necessity of shareholder approval. The document is a formal disclosure of a financing-related transaction but does not contain financial statements or detailed financial performance data. It is not a full financial report, earnings release, or management discussion. The content fits best under Capital/Financing Update (CAP) as it concerns borrowing and financing activities involving related parties.
2024-04-29 Chinese
2023年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度董事会审计委员会履职情况报告" which translates to "2023 Annual Report on the Board Audit Committee's Performance." It details the audit committee's activities, meetings, oversight of financial reports, internal controls, and external audit supervision throughout the year 2023. The content focuses on the audit committee's work and their evaluation of financial reporting and internal controls, which aligns with an Audit Report / Information filing rather than a full Annual Report or other categories. The document length is 3337 characters, which is sufficient for a detailed report but not a brief announcement. There is no indication that this is a report publication announcement or a certification letter. Therefore, the document fits best under the Audit Report / Information (AR) category. FY 2023
2024-04-29 Chinese
关于对会计师事务所2023年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (auditor) for the company's 2023 annual audit. It discusses the auditor's qualifications, audit procedures, and the audit results for the 2023 fiscal year, including the issuance of an unqualified audit opinion on the company's financial statements and internal controls. The document is not the full annual report itself but rather an assessment of the auditor's work related to the annual report audit. It is a standalone audit-related report focusing on the auditor's performance and compliance with auditing standards. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 1618 characters, which is short but contains substantive audit evaluation content, not just an announcement or certification, so it is not RPA or RNS. FY 2023
2024-04-29 Chinese
2023年度独立董事述职报告（吴冬）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2023 by an independent director of the company. It details the director's activities, attendance at board and shareholder meetings, independence status, communication with auditors, and oversight of company governance and compliance. It does not contain financial statements or quarterly/annual financial results, nor is it an announcement of voting results or a regulatory filing. The content is focused on management and board oversight activities, which aligns with Board/Management Information filings. The document length is 3308 characters, which is relatively short but contains substantive content about the director's role and activities rather than just an announcement or certification. Therefore, the best fitting category is Board/Management Information (MANG).
2024-04-29 Chinese
2023年第四季度主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a quarterly announcement of key operating data for the fourth quarter of 2023, including contract signings and sales volumes. It is explicitly labeled as an announcement of main operating data and is relatively short (687 characters). It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). Instead, it provides summarized operational metrics and is presented as an announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-29 Chinese
关于公司2023年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's 2023 annual fundraising (募集资金) storage and usage situation, including amounts raised, usage by projects, compliance with regulatory requirements, and auditor and sponsor opinions. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes financial figures related to fundraising and usage. The document is not a general annual report or earnings release but a specialized report focused on the management and use of raised funds. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (7941 characters) and detailed financial data support it being a substantive report rather than a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-04-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.